Arkema Earnings Call: Cash Strength Amid Margin Pressure

Arkema S.A. ((ARKAY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Arkema’s latest earnings call painted a mixed but ultimately balanced picture for investors. Management acknowledged significant pressure on sales and margins from weak macro conditions, currency headwinds and cyclical downturns, yet highlighted strong cash generation, accelerated cost savings and solid progress on strategic growth and climate targets.

Strong Cash Generation Underpins Investment Case

Arkema surprised positively on cash, delivering recurring operating cash flow of €464 million, well above its revised guidance of €300 million. Free cash flow reached €390 million, translating into a robust 88% conversion of EBITDA into operating cash despite a difficult backdrop.

Balance Sheet Resilience and Deleveraging Efforts

Net debt including hybrid bonds edged down to €3.2 billion, putting leverage at 2.5 times last‑12‑month EBITDA and confirming a relatively comfortable capital structure. The group also redeemed €300 million of hybrid bonds, reducing outstanding hybrids to €800 million and modestly de‑risking the balance sheet.

Accelerated Cost Savings and Efficiency Measures

The company delivered about €90 million of fixed and variable cost savings in 2025, almost double its initial annual target. Management has launched broader efficiency plans, including more than 2% headcount reduction in 2025 and roughly 3% annual cuts over the next three years, aiming for €250 million cumulative savings ahead of schedule.

Project Ramp‑Ups Support Earnings Despite Headwinds

Major strategic projects contributed roughly €60 million of additional EBITDA in 2025, partially offsetting market softness. For 2026, Arkema expects around €50 million more EBITDA from new projects, with a key PVDF capacity expansion in the U.S. slated to start up in the first half and lift regional capacity by about 15%.

Disciplined CapEx and Focused Capital Allocation

Capital expenditure was trimmed to €636 million in 2025 as Arkema tightened its investment filter in a tougher environment. For 2026, CapEx is guided further down to €600 million, with spending concentrated on targeted, high‑return projects designed to deliver quicker paybacks and support specialty growth.

Growth Engines in High‑Value Specialty Markets

Despite cyclical pressures elsewhere, Arkema reported strong momentum in high‑value niches such as batteries, sports, 3D printing, healthcare and new‑generation low‑GWP fluorospecialties. Sales in these areas grew 16% year on year, underpinned by ongoing R&D and strategic partnerships intended to deepen product differentiation.

Stable Dividend Signals Strategic Confidence

The board proposed maintaining the dividend at €3.60 per share even after a year of lower revenues and earnings. This stable payout is meant to signal confidence in Arkema’s business model, cash‑generation ability and longer‑term strategy, and may appeal to income‑focused investors.

Notable Progress on Climate and Sustainability Targets

Arkema highlighted strong progress on its environmental roadmap, reporting a 48.7% reduction in Scope 1 and 2 emissions versus its target baseline by the end of 2025. The company also strengthened ambitions around water withdrawals and waste treatment, reinforcing the role of sustainability in its investment and portfolio choices.

Revenue Decline Reflects Weak Volumes and FX Headwinds

Group revenues slipped 5% to €9.1 billion, hurt by a 1.6% drop in volumes and a 2.1% negative price effect. Currency movements, notably a weaker U.S. dollar against the euro, shaved a further 2.9% off sales, underscoring the sensitivity of results to global macro and FX trends.

EBITDA Contraction and Margin Pressure Weigh on Earnings

Group EBITDA fell to €1.25 billion, with the margin easing to 13.8%, a noticeable step down from prior expectations and last year’s levels. Recurring EBIT came in at €564 million, implying a recurring EBIT margin of 6.2% and highlighting the impact of softer volumes, pricing pressure and a higher cost base.

Currency and Financial Charges Drag on Profitability

Reported EBITDA absorbed about €40 million of negative currency impact, compounding operational challenges in 2025. Financial expenses increased to -€125 million as bond interest rose and interest income on invested cash declined, further squeezing the bottom line for shareholders.

Cyclical Weakness in Acrylics and Legacy Refrigerants

A low point in the cycle for upstream acrylics and a marked decline in old‑generation refrigerants accounted for a large part of the EBITDA drop. Management cautioned that these activities are likely to remain volatile, with some legacy refrigerant business expected to fade over the coming years as the portfolio transitions.

Seasonal Q4 Slump and Destocking Hit Demand

The fourth quarter was particularly weak, as usual seasonality combined with heavy customer destocking, especially in Europe and the U.S. This amplified the slowdown in sales and EBITDA across Adhesives and Advanced Materials, and management admitted visibility for 2026 demand trends remains limited.

Nonrecurring Items and Restructuring Weigh on Reported Results

Nonrecurring items totaled €276 million, including €144 million of purchase price allocation depreciation and €132 million of one‑off charges, mainly restructuring linked to a hydrogen peroxide site. A €74 million nonrecurring cash outflow also reduced free cash flow, partially masking the underlying strength of recurring cash generation.

Pricing Pressure and Lower Realized Prices

The group’s overall price effect was down 2.1%, driven mainly by acrylics and the transition in refrigerants, which forced pricing resets. Other businesses also saw a modest 0.9% price decline, reflecting lower raw‑material costs being passed through to customers in line with contract structures.

Higher Depreciation Adds to Cost Base Pressure

Recurring depreciation on fixed assets rose to €687 million, up from the prior year due to recent acquisitions and the ramp‑up of new production units. This higher non‑cash cost weighed on recurring EBIT and underlines the importance of ensuring new capacity is quickly filled with profitable specialty volumes.

Guidance Points to Modest EBITDA Growth in 2026

For 2026, Arkema guides to slight EBITDA growth at constant FX versus the €1.25 billion delivered in 2025, helped by around €50 million extra EBITDA from projects. CapEx is set to decline to €600 million, working capital should hover near 12.5% of sales, and recurring cash generation and ~88% cash conversion are expected to stay broadly in line, supported by €250 million targeted cost savings by 2026.

Arkema’s earnings call outlined a year of weaker sales and margins but strong financial discipline and strategic execution. While cyclical and macro headwinds remain and visibility is limited, the company’s cash generation, cost‑cutting momentum, project ramp‑ups and steadied leverage provide a constructive base for investors watching how 2026 demand unfolds.